CORE--PATIENT ACCESS, DATA MANAGEMENT AND TISSUE CULTURE

治疗相关白血病是联合治疗的晚期并发症 细胞毒性药物和/或放射治疗。这是一种独特的临床病理。 以及通常致命的细胞遗传学综合征。其中一个特别的 该计划的特点是，四个单独的项目是 完全取决于患者的材料，因为大多数问题 要解决的问题源于患者个人反应的性质。 也就是说，为什么一些患者会发展为继发性白血病，而另一些患者 不?除了患者登记、图表审查、样本收集 和数据采集，我们再次建议将其合并到原始 为数据库协调、统计分析和 计算。此外，我们建议扩大对遗传基因的研究。 通过建立一个登记系统来增加白血病的易感性 原发和继发性白血病家系，以确定家族性 聚合。 患者访问中心具有获取样本的双重任务 以及数据管理和分析。这些函数对于 成功完成拟议的调查，并需要 支持和联系将来自各种不同领域的成果 实验室。通过这种方式，可以传播对数据的中期分析 迅速在项目调查人员之间，和独特的患者资源 可能会以最有成效的方式分享。 为了提供对患者材料的有序访问并保持 记录，我们建议继续使用我们的核心组件来管理这些 与过去10年一样发挥作用。关于特定临床的请求 材料(血液或骨髓细胞、肿瘤组织、口腔拭子DNA、 或来自特定患者或家庭成员的细胞系)将被定向 由每个项目PI to the Core。采集完成后，临床标本 将登录并传输以进行处理并交付给 个别项目。数据表格将保存在安全的文件柜中，以及 研究数据将保存在密码下的电子文件中 保安。

Therapy-related leukemia is a late complication of treatment with cytotoxic drugs and/or irradiation. It is a distinctive clinicopathological and cytogenetic syndrome that is usually fatal. One of the special features of this program is that the four individual projects are absolutely dependent upon patient material, since most of the questions to be addressed arise from the nature of individual patient responses. That is, why do some patients develop secondary leukemia and others not? In addition to patient enrollment, chart review, specimen collection and data acquisition, we propose again to incorporate within the original Core formal support for database coordination, statistical analysis, and computation. In addition, we propose to expand our studies on genetic susceptibility for the development of leukemia by establishing a registry of primary and secondary leukemia families in order to ascertain familial aggregations. The Patient Access core has the dual missions of specimen acquisition and data management and analysis. These functions are critical to the successful completion of the proposed investigations and necessary to support and link together the results that will come from the various laboratories. In this way, interim analyses of data may be disseminated promptly among the project investigators, and unique patient resources may be shared in the most productive manner. In order to provide an orderly access to patient material and to maintain records, we propose to continue our Core component to manage these functions as it has for the past 10 years. Requests for specific clinical materials (blood or marrow cells, tumor tissues, DNA from buccal swabs, or cell lines from specific patients or family members) will be directed by each project PI to the Core. After collection, the clinical specimens will be logged in and transported for processing and delivery to the individual projects. Data forms will be kept in secure file cabinets, and research data will be maintained in electronic files under password security.